What is Achira?
Founded in 2023 and headquartered in the United States, Achira is at the forefront of biotechnology innovation. The company specializes in creating sophisticated atomistic simulation models. These models leverage a powerful combination of geometric deep learning, physics, quantum chemistry, and statistical mechanics. By integrating these advanced methodologies, Achira aims to significantly accelerate and improve the efficiency of drug discovery processes, addressing critical challenges in pharmaceutical research and development.
How much funding has Achira raised?
Achira has raised a total of $33M across 1 funding round:
Angel/Seed
$33M
Angel/Seed (2025): $33M with participation from Amplify Partners and NVentures
Key Investors in Achira
Amplify Partners
Amplify Partners is an early-stage investor focused on companies in machine intelligence and computer science, providing deep domain expertise and technical insight to founding teams.
NVentures
NVentures is an upstream exploration firm offering technical and commercial intelligence for the E&P and Energy industry, with a growing focus on hydrogen and new energy opportunities.
What's next for Achira?
The recent major strategic investment signals a pivotal growth phase for Achira. With substantial backing, the company is poised to scale its operations, further refine its proprietary simulation technologies, and potentially expand its market reach. This financing will likely fuel research and development initiatives, enabling Achira to deepen its impact on the drug discovery landscape and solidify its position as a key player in the biotechnology sector.
See full Achira company page
